Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 18:08
07/02/20
07/02
18:08
07/02/20
18:08
GSK

GlaxoSmithKline

$41.22 /

+0.35 (+0.86%)

, UIHC

United Insurance

$7.51 /

+0.03 (+0.40%)

, REGN

Regeneron

$620.76 /

+11.54 (+1.89%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
UIHC United Insurance
$7.51 /

+0.03 (+0.40%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
UIHC United Insurance
$7.51 /

+0.03 (+0.40%)

01/06/20 Wells Fargo
United Insurance downgraded to Underweight at Wells Fargo
01/06/20 Wells Fargo
United Insurance downgraded to Underweight from Equal Weight at Wells Fargo
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

  • 27
    May
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

Hot Stocks
ViiV Healthcare announces FDA approval of Rukobia for HIV » 16:19
07/02/20
07/02
16:19
07/02/20
16:19
GSK

GlaxoSmithKline

$41.22 /

+0.35 (+0.86%)

, PFE

Pfizer

$34.52 /

+0.78 (+2.31%)

ViiV Healthcare, the…

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi Limited as shareholders, announced that the U.S. Food and Drug Administration has approved Rukobia 600 mg extended-release tablets. Rukobia is a novel attachment inhibitor for the treatment of HIV-1 infection indicated for use in combination with other antiretroviral therapies in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection, who are failing their current ARV regimen due to resistance, intolerance or safety considerations. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$34.52 /

+0.78 (+2.31%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
PFE Pfizer
$34.52 /

+0.78 (+2.31%)

07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
07/02/20 SVB Leerink
BioNTech price target raised to $42 from $37 at SVB Leerink
07/01/20 Goldman Sachs
Pfizer COVID-19 vaccine data 'encouraging,' says Goldman Sachs
PFE Pfizer
$34.52 /

+0.78 (+2.31%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

PFE Pfizer
$34.52 /

+0.78 (+2.31%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

PFE Pfizer
$34.52 /

+0.78 (+2.31%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

PFE Pfizer
$34.52 /

+0.78 (+2.31%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

Monday
Hot Stocks
Dynavax, Moderna, Novavax COVID-19 vaccine candidates listed in WHO review » 11:10
06/29/20
06/29
11:10
06/29/20
11:10
DVAX

Dynavax

$8.77 /

-0.335 (-3.68%)

, AZN

AstraZeneca

$52.97 /

+0.27 (+0.51%)

, MRNA

Moderna

$60.91 /

-0.34 (-0.56%)

, SHTDF

Sinopharm Group

$0.00 /

+ (+0.00%)

, NVAX

Novavax

$84.46 /

+7.1 (+9.18%)

, BNTX

BioNTech

$69.51 /

+7.14 (+11.45%)

, PFE

Pfizer

$32.57 /

+0.54 (+1.69%)

, INO

Inovio

$28.29 /

-1.555 (-5.21%)

, GSK

GlaxoSmithKline

$40.91 /

+0.35 (+0.86%)

The World Health…

The World Health Organization released landscape documents that it has prepared "for information purposes only concerning the 2019-2020 global of the novel coronavirus." WHO stated that inclusion of any particular product or entity in any of its landscape documents "does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity." Among the 17 candidate vaccines in clinical evaluation, WHO listed products under development from or in partnership with AstraZeneca (AZN), Moderna (MRNA), Sinopharm Group (SHTDF), Novavax (NVAX), BioNTech (BNTX) and Pfizer (PFE), Inovio (INO), GlaxoSmithKline (GSK) and Dynavax (DVAX), and others. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$32.57 /

+0.54 (+1.69%)

NVAX Novavax
$84.46 /

+7.1 (+9.18%)

MRNA Moderna
$60.91 /

-0.34 (-0.56%)

INO Inovio
$28.29 /

-1.555 (-5.21%)

GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

DVAX Dynavax
$8.77 /

-0.335 (-3.68%)

BNTX BioNTech
$69.51 /

+7.14 (+11.45%)

AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

DVAX Dynavax
$8.77 /

-0.335 (-3.68%)

06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
07/10/19 Cantor Fitzgerald
Dynavax upgraded to Overweight from Neutral at Cantor Fitzgerald
AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
MRNA Moderna
$60.91 /

-0.34 (-0.56%)

06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
06/12/20 Piper Sandler
Moderna preclinical data supports activity of COVID vaccine, says Piper Sandler
06/11/20 Piper Sandler
Moderna, FDA finalize Phase III trial protocol for mRNA-1273, says Piper Sandler
SHTDF Sinopharm Group
$0.00 /

+ (+0.00%)

03/19/20 Goldman Sachs
Sinopharm Group upgraded to Buy from Neutral at Goldman Sachs
NVAX Novavax
$84.46 /

+7.1 (+9.18%)

06/29/20 B. Riley FBR
Novavax price target raised to $106 from $74 at B. Riley FBR
06/29/20 H.C. Wainwright
Novavax price target raised to $101 from $50 at H.C. Wainwright
06/19/20 Cantor Fitzgerald
Novavax price target raised to $88 from $45 at Cantor Fitzgerald
06/05/20
Fly Intel: Top five analyst upgrades
BNTX BioNTech
$69.51 /

+7.14 (+11.45%)

06/25/20 H.C. Wainwright
BioNTech price target lowered to $63 from $69 at H.C. Wainwright
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
PFE Pfizer
$32.57 /

+0.54 (+1.69%)

06/29/20 Mizuho
Pfizer resumed with a Buy at Mizuho
06/25/20 Piper Sandler
Aptevo Therapeutics price target raised to $24 from $18.50 at Piper Sandler
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
INO Inovio
$28.29 /

-1.555 (-5.21%)

06/29/20 H.C. Wainwright
Inovio downgraded to Neutral from Buy at H.C. Wainwright
06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 Cantor Fitzgerald
Inovio price target raised to $45 from $17 at Cantor Fitzgerald
06/26/20 Stifel
Inovio downgraded to Hold from Buy at Stifel
GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
PFE Pfizer
$32.57 /

+0.54 (+1.69%)

NVAX Novavax
$84.46 /

+7.1 (+9.18%)

MRNA Moderna
$60.91 /

-0.34 (-0.56%)

INO Inovio
$28.29 /

-1.555 (-5.21%)

GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

DVAX Dynavax
$8.77 /

-0.335 (-3.68%)

BNTX BioNTech
$69.51 /

+7.14 (+11.45%)

AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

  • 22
    May
  • 19
    May
  • 12
    Feb
  • 06
    Feb
  • 10
    Oct
  • 08
    Aug
PFE Pfizer
$32.57 /

+0.54 (+1.69%)

NVAX Novavax
$84.46 /

+7.1 (+9.18%)

MRNA Moderna
$60.91 /

-0.34 (-0.56%)

INO Inovio
$28.29 /

-1.555 (-5.21%)

GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

PFE Pfizer
$32.57 /

+0.54 (+1.69%)

NVAX Novavax
$84.46 /

+7.1 (+9.18%)

MRNA Moderna
$60.91 /

-0.34 (-0.56%)

INO Inovio
$28.29 /

-1.555 (-5.21%)

GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

DVAX Dynavax
$8.77 /

-0.335 (-3.68%)

BNTX BioNTech
$69.51 /

+7.14 (+11.45%)

AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

PFE Pfizer
$32.57 /

+0.54 (+1.69%)

NVAX Novavax
$84.46 /

+7.1 (+9.18%)

MRNA Moderna
$60.91 /

-0.34 (-0.56%)

INO Inovio
$28.29 /

-1.555 (-5.21%)

GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

DVAX Dynavax
$8.77 /

-0.335 (-3.68%)

BNTX BioNTech
$69.51 /

+7.14 (+11.45%)

AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

Over a week ago
Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 05:55
06/24/20
06/24
05:55
06/24/20
05:55
A

Agilent

$89.36 /

+0.81 (+0.91%)

, ABBV

AbbVie

$97.28 /

+0.03 (+0.03%)

, ADPT

Adaptive Biotechnologies

$46.95 /

+1.04 (+2.27%)

, AZN

AstraZeneca

$54.24 /

+0.8 (+1.50%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$187.74 /

+4.42 (+2.41%)

, BMY

Bristol-Myers

$58.41 /

+0.85 (+1.48%)

, BNTX

BioNTech

$52.80 /

-4.64 (-8.08%)

, CRL

Charles River

$175.05 /

-0.12 (-0.07%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$83.33 /

+0.26 (+0.31%)

, GILD

Gilead

$75.01 /

-0.61 (-0.81%)

, PFE

Pfizer

$32.78 /

-0.33 (-1.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVCR

Novocure

$62.71 /

-0.31 (-0.49%)

, NTRA

Natera

$46.65 /

+0.36 (+0.78%)

, SNY

Sanofi

$52.49 /

-0.06 (-0.11%)

, RUBY

Rubius Therapeutics

$6.52 /

-0.02 (-0.31%)

, NEO

NeoGenomics

$29.05 /

+0.49 (+1.72%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$25.06 /

-0.75 (-2.91%)

, QGEN

Qiagen

$42.87 /

+0.31 (+0.73%)

, LLY

Eli Lilly

$159.35 /

-1.06 (-0.66%)

, PKI

PerkinElmer

$99.11 /

+1.08 (+1.10%)

, GSK

GlaxoSmithKline

$41.60 /

+0.37 (+0.90%)

, ILMN

Illumina

$367.22 /

+7.02 (+1.95%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

NTRA Natera
$46.65 /

+0.36 (+0.78%)

NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$175.05 /

-0.12 (-0.07%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

A Agilent
$89.36 /

+0.81 (+0.91%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

06/23/20
Fly Intel: Top five analyst upgrades
06/23/20 Atlantic Equities
AbbVie upgraded to Overweight from Neutral at Atlantic Equities
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/23/20 Berenberg
Bayer price target raised to EUR 86 from EUR 82 at Berenberg
06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$175.05 /

-0.12 (-0.07%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$83.33 /

+0.26 (+0.31%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$75.01 /

-0.61 (-0.81%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$32.78 /

-0.33 (-1.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$62.71 /

-0.31 (-0.49%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.65 /

+0.36 (+0.78%)

06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
06/23/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
ILMN Illumina
$367.22 /

+7.02 (+1.95%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

NTRA Natera
$46.65 /

+0.36 (+0.78%)

NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

CRL Charles River
$175.05 /

-0.12 (-0.07%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

Recommendations
Inovio price target raised to $24 from $18 at Maxim » 10:00
06/23/20
06/23
10:00
06/23/20
10:00
INO

Inovio

$16.49 /

+1.195 (+7.81%)

, AZN

AstraZeneca

$53.36 /

-0.08 (-0.15%)

, JNJ

Johnson & Johnson

$143.64 /

+0.26 (+0.18%)

, MRK

Merck

$78.16 /

+1.45 (+1.89%)

, MRNA

Moderna

$63.33 /

-1.42 (-2.19%)

, PFE

Pfizer

$33.19 /

+0.08 (+0.24%)

, SNY

Sanofi

$52.65 /

+0.1 (+0.19%)

, GSK

GlaxoSmithKline

$41.60 /

+0.37 (+0.90%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy raised the firm's price target on Inovio (INO) to $24 from $18 and keeps a Buy rating on the shares. The analyst notes that Inovio announced that the Department of Defense has awarded the company a contract for $71M to manufacture/procure CELLECTRA vaccine delivery devices. He views this as a de-risking event for Inovio's INO-4800 COVID vaccine, which should be reporting the Phase 1 data this summer, followed by a Phase 2/3 efficacy trial this summer as well. As such, McCarthy has reduced the risk adjustment in his model to 70%, from 80%. The analyst notes that Operation Warp Speed recently announced its "finalists" for vaccine production, namely AstraZeneca (AZN), J&J (JNJ), Merck (MRK), Moderna (MRNA) and Pfizer (PFE). No details were provided but perhaps it should have included Inovio, he contends, adding that Sanofi (SNY) and GlaxoSmithKline (GSK) were also left out, both of which are leading vaccine and vaccine adjuvant producers.

ShowHide Related Items >><<
SNY Sanofi
$52.65 /

+0.1 (+0.19%)

PFE Pfizer
$33.19 /

+0.08 (+0.24%)

MRNA Moderna
$63.33 /

-1.42 (-2.19%)

MRK Merck
$78.16 /

+1.45 (+1.89%)

JNJ Johnson & Johnson
$143.64 /

+0.26 (+0.18%)

INO Inovio
$16.49 /

+1.195 (+7.81%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

AZN AstraZeneca
$53.36 /

-0.08 (-0.15%)

INO Inovio
$16.49 /

+1.195 (+7.81%)

06/04/20 Cantor Fitzgerald
Inovio, Novavax COVID vaccines should not be disregarded, says Cantor
06/01/20 Piper Sandler
Context 'may be necessary' for Inovio's INO-5401 GBM update, says Piper Sandler
05/21/20 Benchmark
Inovio initiated with a Buy at Benchmark
05/20/20 Roth Capital
Most of Inovio COVID-19 vaccine data 'over two months old,' says Roth Capital
AZN AstraZeneca
$53.36 /

-0.08 (-0.15%)

06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
JNJ Johnson & Johnson
$143.64 /

+0.26 (+0.18%)

05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
MRK Merck
$78.16 /

+1.45 (+1.89%)

06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/12/20 Wolfe Research
Merck downgraded to Peer Perform from Outperform at Wolfe Research
MRNA Moderna
$63.33 /

-1.42 (-2.19%)

06/12/20 Piper Sandler
Moderna preclinical data supports activity of COVID vaccine, says Piper Sandler
06/11/20 Piper Sandler
Moderna, FDA finalize Phase III trial protocol for mRNA-1273, says Piper Sandler
06/08/20 Barclays
Moderna initiated with an Overweight at Barclays
06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
PFE Pfizer
$33.19 /

+0.08 (+0.24%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
06/16/20 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
SNY Sanofi
$52.65 /

+0.1 (+0.19%)

06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
06/09/20 Morgan Stanley
Sanofi price target raised to EUR 107 from EUR 101 at Morgan Stanley
GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
SNY Sanofi
$52.65 /

+0.1 (+0.19%)

PFE Pfizer
$33.19 /

+0.08 (+0.24%)

MRNA Moderna
$63.33 /

-1.42 (-2.19%)

MRK Merck
$78.16 /

+1.45 (+1.89%)

JNJ Johnson & Johnson
$143.64 /

+0.26 (+0.18%)

INO Inovio
$16.49 /

+1.195 (+7.81%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

AZN AstraZeneca
$53.36 /

-0.08 (-0.15%)

SNY Sanofi
$52.65 /

+0.1 (+0.19%)

PFE Pfizer
$33.19 /

+0.08 (+0.24%)

MRNA Moderna
$63.33 /

-1.42 (-2.19%)

MRK Merck
$78.16 /

+1.45 (+1.89%)

JNJ Johnson & Johnson
$143.64 /

+0.26 (+0.18%)

INO Inovio
$16.49 /

+1.195 (+7.81%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

AZN AstraZeneca
$53.36 /

-0.08 (-0.15%)

SNY Sanofi
$52.65 /

+0.1 (+0.19%)

PFE Pfizer
$33.19 /

+0.08 (+0.24%)

MRNA Moderna
$63.33 /

-1.42 (-2.19%)

MRK Merck
$78.16 /

+1.45 (+1.89%)

INO Inovio
$16.49 /

+1.195 (+7.81%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

AZN AstraZeneca
$53.36 /

-0.08 (-0.15%)

SNY Sanofi
$52.65 /

+0.1 (+0.19%)

PFE Pfizer
$33.19 /

+0.08 (+0.24%)

MRNA Moderna
$63.33 /

-1.42 (-2.19%)

MRK Merck
$78.16 /

+1.45 (+1.89%)

JNJ Johnson & Johnson
$143.64 /

+0.26 (+0.18%)

INO Inovio
$16.49 /

+1.195 (+7.81%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

AZN AstraZeneca
$53.36 /

-0.08 (-0.15%)

Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 04:55
06/23/20
06/23
04:55
06/23/20
04:55
A

Agilent

$88.55 /

-0.27 (-0.30%)

, ABBV

AbbVie

$97.25 /

+0.53 (+0.55%)

, ADPT

Adaptive Biotechnologies

$45.91 /

+1.24 (+2.78%)

, AZN

AstraZeneca

$53.44 /

+0.39 (+0.74%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$183.32 /

+0.75 (+0.41%)

, BMY

Bristol-Myers

$57.56 /

+1.22 (+2.17%)

, BNTX

BioNTech

$57.44 /

+6.02 (+11.71%)

, CRL

Charles River

$175.17 /

-3.21 (-1.80%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$83.07 /

+4.14 (+5.25%)

, GILD

Gilead

$75.62 /

-1.61 (-2.08%)

, PFE

Pfizer

$33.11 /

-0.32 (-0.96%)

, NVS

Novartis

$90.58 /

-0.55 (-0.60%)

, NVCR

Novocure

$63.02 /

-0.33 (-0.52%)

, NTRA

Natera

$46.29 /

-0.16 (-0.34%)

, SNY

Sanofi

$52.55 /

+0.25 (+0.48%)

, RUBY

Rubius Therapeutics

$6.54 /

+0.07 (+1.08%)

, NEO

NeoGenomics

$28.56 /

+0.17 (+0.60%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$25.81 /

-0.23 (-0.88%)

, QGEN

Qiagen

$42.56 /

-0.03 (-0.07%)

, LLY

Eli Lilly

$160.41 /

+0.51 (+0.32%)

, PKI

PerkinElmer

$98.03 /

-0.48 (-0.49%)

, GSK

GlaxoSmithKline

$41.23 /

+0.11 (+0.27%)

, ILMN

Illumina

$360.20 /

-10.23 (-2.76%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

NTRA Natera
$46.29 /

-0.16 (-0.34%)

NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$175.17 /

-3.21 (-1.80%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

A Agilent
$88.55 /

-0.27 (-0.30%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
06/04/20 BMO Capital
Dicamba ruling likely a mid-term positive for Corteva, says BMO Capital
BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$175.17 /

-3.21 (-1.80%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$83.07 /

+4.14 (+5.25%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$75.62 /

-1.61 (-2.08%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$33.11 /

-0.32 (-0.96%)

06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
06/16/20 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
NVS Novartis
$90.58 /

-0.55 (-0.60%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$63.02 /

-0.33 (-0.52%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.29 /

-0.16 (-0.34%)

06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
06/09/20 Morgan Stanley
Sanofi price target raised to EUR 107 from EUR 101 at Morgan Stanley
RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
06/16/20 Guggenheim
Eli Lilly upgraded to Buy from Neutral at Guggenheim
PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
ILMN Illumina
$360.20 /

-10.23 (-2.76%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

NTRA Natera
$46.29 /

-0.16 (-0.34%)

NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

CRL Charles River
$175.17 /

-3.21 (-1.80%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 08:42
06/22/20
06/22
08:42
06/22/20
08:42
A

Agilent

$88.82 /

+0.6 (+0.68%)

, ABBV

AbbVie

$96.72 /

+0.45 (+0.47%)

, ADPT

Adaptive Biotechnologies

$44.67 /

+0.14 (+0.31%)

, AZN

AstraZeneca

$53.05 /

+0.39 (+0.74%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$182.57 /

+5.09 (+2.87%)

, BMY

Bristol-Myers

$56.34 /

+0.35 (+0.63%)

, BNTX

BioNTech

$51.42 /

+0.48 (+0.94%)

, CRL

Charles River

$178.38 /

-0.31 (-0.17%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$78.93 /

-0.62 (-0.78%)

, GILD

Gilead

$77.23 /

+3.18 (+4.29%)

, PFE

Pfizer

$33.43 /

+0.2 (+0.60%)

, NVS

Novartis

$91.13 /

+1.47 (+1.64%)

, NVCR

Novocure

$63.35 /

+0.83 (+1.33%)

, NTRA

Natera

$46.45 /

+0.43 (+0.93%)

, SNY

Sanofi

$52.30 /

+0.84 (+1.63%)

, RUBY

Rubius Therapeutics

$6.47 /

+0.09 (+1.41%)

, NEO

NeoGenomics

$28.39 /

+0.145 (+0.51%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$26.04 /

-1.46 (-5.31%)

, QGEN

Qiagen

$42.59 /

+0.17 (+0.40%)

, LLY

Eli Lilly

$159.90 /

-1.14 (-0.71%)

, PKI

PerkinElmer

$98.51 /

+0.565 (+0.58%)

, GSK

GlaxoSmithKline

$41.12 /

+0.18 (+0.44%)

, ILMN

Illumina

$370.43 /

+8.18 (+2.26%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

NTRA Natera
$46.45 /

+0.43 (+0.93%)

NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$178.38 /

-0.31 (-0.17%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

A Agilent
$88.82 /

+0.6 (+0.68%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
06/04/20 BMO Capital
Dicamba ruling likely a mid-term positive for Corteva, says BMO Capital
BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$178.38 /

-0.31 (-0.17%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$78.93 /

-0.62 (-0.78%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$77.23 /

+3.18 (+4.29%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$33.43 /

+0.2 (+0.60%)

06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
06/16/20 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
06/08/20 Piper Sandler
Opko Health, Pfizer data show IGF-1 normal at ENDO, says Piper Sandler
NVS Novartis
$91.13 /

+1.47 (+1.64%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$63.35 /

+0.83 (+1.33%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.45 /

+0.43 (+0.93%)

06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
05/07/20 JPMorgan
Natera upgraded to Overweight from Neutral at JPMorgan
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
06/09/20 Morgan Stanley
Sanofi price target raised to EUR 107 from EUR 101 at Morgan Stanley
RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
06/16/20 Guggenheim
Eli Lilly upgraded to Buy from Neutral at Guggenheim
PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
ILMN Illumina
$370.43 /

+8.18 (+2.26%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

NTRA Natera
$46.45 /

+0.43 (+0.93%)

NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

CRL Charles River
$178.38 /

-0.31 (-0.17%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

Hot Stocks
SpringsWorks Therapeutics: Dosing begins in Phase 1b study of nirogacestat » 06:38
06/22/20
06/22
06:38
06/22/20
06:38
SWTX

SpringsWorks Therapeutics

$44.98 /

-3.53 (-7.28%)

, GSK

GlaxoSmithKline

$41.12 /

+0.18 (+0.44%)

SpringWorks Therapeutics…

SpringWorks Therapeutics (SWTX) announced that the first patient has been dosed in a Phase 1b clinical trial evaluating SpringWorks Therapeutics' investigational gamma secretase inhibitor, nirogacestat, in combination with GlaxoSmithKline's (GSK) investigational anti-B-cell maturation antigen antibody-drug conjugate, belantamab mafodotin, in patients with relapsed or refractory multiple myeloma. The nirogacestat and belantamab mafodotin combination is being evaluated as a sub-study in GSK's ongoing DREAMM-5 platform trial. The Phase 1b combination trial is being advanced pursuant to a global clinical trial collaboration agreement that SpringWorks and GSK entered into in June 2019. Under the terms of the agreement, GSK is sponsoring and conducting the Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the combination, and is assuming all development costs associated with the study, other than expenses related to the manufacturing of nirogacestat and certain expenses related to intellectual property rights. SpringWorks and GlaxoSmithKline have formed a joint development committee to help manage and oversee the clinical study.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$44.98 /

-3.53 (-7.28%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

SWTX SpringsWorks Therapeutics
$44.98 /

-3.53 (-7.28%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
SWTX SpringsWorks Therapeutics
$44.98 /

-3.53 (-7.28%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

Recommendations
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays » 14:26
06/19/20
06/19
14:26
06/19/20
14:26
GSK

GlaxoSmithKline

$40.83 /

-0.11 (-0.27%)

Barclays analyst Emmanuel…

Barclays analyst Emmanuel Papadakis called the announcement by GlaxoSmithKline that the FDA will convene a meeting of the Oncologic Drugs Advisory Committee to review the company's Biologics License Application for belantamab mafodotin for the potential treatment of relapsed or refractory multiple myeloma a "surprise" that endorses caution about the risk-benefit of the company's "key myeloma asset." Papadakis, who thinks ocular toxicity is likely the reason for the FDA convening the Adcom meeting, has an Underweight rating on Glaxo shares.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$40.83 /

-0.11 (-0.27%)

GSK GlaxoSmithKline
$40.83 /

-0.11 (-0.27%)

06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
04/30/20 Barclays
GlaxoSmithKline price target raised to 1,550 GBp from 1,450 GBp at Barclays
GSK GlaxoSmithKline
$40.83 /

-0.11 (-0.27%)

GSK GlaxoSmithKline
$40.83 /

-0.11 (-0.27%)

GSK GlaxoSmithKline
$40.83 /

-0.11 (-0.27%)

GSK GlaxoSmithKline
$40.83 /

-0.11 (-0.27%)

Hot Stocks
GSK announces FDA Advisory Committee meeting to review belantamab mafodotin » 10:32
06/19/20
06/19
10:32
06/19/20
10:32
GSK

GlaxoSmithKline

$41.33 /

+0.39 (+0.95%)

GlaxoSmithKline announced…

GlaxoSmithKline announced the U.S. Food and Drug Administration will convene a meeting of the Oncologic Drugs Advisory Committee to review data supporting the company's Biologics License Application for belantamab mafodotin for the potential treatment of patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. The ODAC will meet virtually on 14 July 2020. Belantamab mafodotin received Breakthrough Therapy Designation in 2017, and the BLA was granted Priority Review status by the FDA in January 2020 based on data from the pivotal DREAMM-2 study. Six-month primary results from the study were published in The Lancet Oncology and follow-up data were presented at the 2020 American Society of Clinical Oncology annual meeting. Belantamab mafodotin is a potential humanised, anti-BCMA being investigated in a robust clinical trial programme for the treatment of multiple myeloma. BCMA is a cell-surface protein that plays an important role in the survival of plasma cells and is universally expressed in patients with multiple myeloma.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$41.33 /

+0.39 (+0.95%)

GSK GlaxoSmithKline
$41.33 /

+0.39 (+0.95%)

06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
04/30/20 Barclays
GlaxoSmithKline price target raised to 1,550 GBp from 1,450 GBp at Barclays
GSK GlaxoSmithKline
$41.33 /

+0.39 (+0.95%)

GSK GlaxoSmithKline
$41.33 /

+0.39 (+0.95%)

GSK GlaxoSmithKline
$41.33 /

+0.39 (+0.95%)

GSK GlaxoSmithKline
$41.33 /

+0.39 (+0.95%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.